Uğur ÜYETÜRK, Ahmet METİN, Ümmügül ÜYETÜRK

Bolu ilindeki testis kanserli hastaların retrospektif analizi

Amaç: Tests kanseri (Tca) erkeklerde görülen ürogenital malignitelerin yaklaşık %20sini, tüm erkek maligni- telerinin yaklaşık %1-2sini oluşturmasına rağmen, 15-35 yaş arası en sık görülen solid kanserlerdir. Kriptorşi- dizm, testküler mikrolitasis, Klinifelter ve Down Sendromu Tca için risk faktörleridir. Tcalerinin %95i germinaldokudan köken alır. Bu tümörler seminomatöz ve nonseminomatöz (embriyonel hücreli karsinom, teratom,koryokarsinom, yolk kesesi tümörü) olarak iki gruba ayrılmaktadır. Biz bu çalışmada, bölgemizde yaşayan Tcatanısı almış hastaların genel özelliklerini ve tedavi seçenekle rini retrospektf olarak değerlendirmeyi amaçladık.Gereç ve Yöntemler: 01.01.2012-30.07.2013 tarihleri arasında Bolu Abant İzzet Baysal Üniversitesi Tıp Fakülte -si, tbbi onkoloji polikliniğine başvuran Tcali hastaların demografk özellikleri ve tedavi seçenekleri retrospektfolarak değerlendirildi. Bulgular: Bu süre içinde median yaşı 31(22-45) yıl olan 15 hastanın başvurduğu bulundu. İlk başvuru şikayetolarak 11nunda (%74) testste kitle, 2sinde (%13) ağrı, 2sinde (%13) kitle ile birlikte ağrı vardı. Hastaların14ünde tümör unilateral, 1inde bilateraldi. Tümör boyutu ortalama 4(0.8-10) cmdi. Hastaların tümörlerinin7si seminomatöz, 7si nonseminomatöz ve bilateral tümörlü hastanın sağ testsi seminomatöz, diğeri nonse - minomatöz histolojiye sahipt. Orşiektomi sonrası seminomatöz evre IA olan 2 hastaya karboplatn, 1 hastayaizlem, evre IB olan 2 hastaya karboplatn, 1 hastaya izlem, evre IIB olan 1 hastaya bleomisin, etoposid, sisplatn(BEP) kemoterapisi verildiği, nonseminomatöz evre IA 2 hastaya izlem, evre II ve üzeri hastalara ise BEP kemoterapisi verildiği görüldü. Sonuç: Bolu ilindeki Tcali hastaların değerlendirildiği bu retrospektf analiz sonuçları literatür ile uyumlu bulundu. Türkiye verilerini elde edebilmek için diğer illerinde dahil edileceği, daha fazla hasta katlımıyla yapılacakçalışmaların gerekli olduğunu düşünmekteyiz.

Retrospectve analysis of patents with Testcular cancer in Bolu province

Objectve: ATestcular cancer (Tca) consists of approximately %20 of urogenital malignancy in men, andapproximately %1 to 2 of all male malignancies. Tca is the most common solid tumor in males aged between15 to 35 years. There are many risk factors related to Tca such as cryptorchidism, testcular microlithiasis,klinefelter and Down syndrome. 95% of Tca is derived from germinal tssue. Germ cell tumor is classifed intotwo groups: seminomatous and nonseminomatous (embryonic carcinoma cell, teratoma, choriocarcinoma,yolk sac tumor). In this study, we aimed to evaluate general characteristcs and treatment modalites of thepatents with diagnosis of Tca living in our region.Material and Methods: Demographic characteristcs and treatment modalites of the patents with Tcafollowed at Bolu Abant İzzet Baysal University Medicine Faculty, Medical Oncology outpatent clinic between01.01.2012 and 30.07.2013 were evaluated retrospectvely. Results: Fifeen patents with median age of 31 (22-45) were included in the study. As the frst compliant, 11patents (%74) reported a mass within the tests, 2 patents (%13) reported pain, and 2 patents (%13) claimedboth pain and mass. The tumor was unilateral in 14 patents and bilateral in 1 patent. The median tumor sizewas 4 (0.8-10) cm. 7 patents had seminomatous histology and 7 patents had nonseminomatous histology.The patent with bilateral tumor had seminomatous histology in the right tests and nonseminomatoushistology in the lef tests. Afer orchiectomy, two patents with seminomatous stage IA were given carboplatnand one patent was followed without chemotherapy; two patents with stage IB were given carboplatnand one patent was followed without chemotherapy; one patent with stage IIB was given bleomycin,etoposide, cisplatn (BEP) chemotherap; 2 patents with nonseminomatous stage IA were followed withoutchemotherapy; the patentswith stage II and above were given BEP chemotherapy.Conclusion: We concluded that our results were in consistent with the literature. We assumed that furtherstudies are needed in other part of the country to obtain the data of Turkish populaton.

PDF

___

1. Parkin DM, Ferlay J, Curado MP, Bray F, Edwards B, Shin HR, et al. Fify years of cancer incidence: CI5 IIX. Internatonal Journal of Cancer. 2010;127(12):2918-27.
2. Garner MJ, Turner MC, Ghadirian P, Krewski D. Epidemiology of testcular cancer: an overview. Internatonal Journal of Cancer. 2005;116(3):331-9.
3. Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testcular cancer worldwide: a review. The Journal of Urology. 2003;170(1):5-11.
4. Ekbom A, Richiardi L, Akre O, Montgomery SM, Sparen P. Age at immigraton and duraton of stay in relaton to risk for testcular cancer among Finnish immigrants in Sweden. Journal of the Natonal Cancer Insttute. 2003;95(16):1238- 40.
5. Zheng T, Holford TR, Ma Z, Ward BA, Flannery J, Boyle P. Contnuing increase in incidence of germ-cell tests cancer in young adults: experience from Connectcut, USA, 1935- 1992. Internatonal Journal of Cancer. 1996;65(6):723-9.
6. Batata MA, Chu FC, Hilaris BS, Whitmore WF, Golbey RB. Testcular cancer in cryptorchids. Cancer. 1982;49(5):1023- 30.
7. Hemminki K, Chen B. Familial risks in testcular cancer as aetological clues. Internatonal journal of andrology. 2006;29(1):205-10.
8. Lyter DW, Bryant J, Thackeray R, Rinaldo CR, Kingsley LA. Incidence of human immunodefciency virus-related and nonrelated malignancies in a large cohort of homosexual men. Journal of Clinical Oncology. 1995;13(10):2540-6.
9. Dieckmann KP, Rube C, Henke RP. Associaton of Downs syndrome and testcular cancer. The Journal of Urology. 1997;157(5):1701-4.
10. Hasle H, Mellemgaard A, Nielsen J, Hansen J. Cancer incidence in men with Klinefelter syndrome. Britsh Journal of Cancer. 1995;71(2):416-20.
11. Tan IB, Ang KK, Ching BC, Mohan C, Toh CK, Tan MH. Testcular microlithiasis predicts concurrent testcular germ cell tumors and intratubular germ cell neoplasia of unclassifed type in adults: a meta-analysis and systematc review. Cancer. 2010;116(19):4520-32.
12. Siegel R, Naishadham D, Jemal A. Cancer statstcs, 2013. CA Cancer J Clin. 2013;63(1):11-30.
13. Nikzas D, Champion A, Fox M. Germ cell tumours of tests: prognostc factors and results. European urology. 1989;18(4):242-7.
14. Holmes L, Jr., Escalante C, Garrison O, Foldi BX, Ogungbade GO, Essien EJ, et al. Testcular cancer incidence trends in the USA (1975-2004): plateau or shifing racial paradigm? Public Health. 2008;122(9):862-72.
15. Krag Jacobsen G, Barlebo H, Olsen J, Schultz HP, Starklint H, Sogaard H, et al. Testcular germ cell tumours in Denmark 1976-1980. Pathology of 1058 consecutve cases. Acta radiologica Oncology. 1984;23(4):239-47.
16. Wood HM, Elder JS. Cryptorchidism and testcular cancer: separatng fact from fcton. The Journal of Urology. 2009;181(2):452-61.
17. Dieckmann KP, Pichlmeier U. Clinical epidemiology of testcular germ cell tumors. World Journal of Urology. 2004;22(1):2-14.
18. Campbell HE. Incidence of malignant growth of the undescended testcle: a critcal and statstcal study. Archives of Surgery. 1942;44(2):353.
19. Germa-Lluch JR, Garcia del Muro X, Maroto P, Paz-Ares L, Arranz JA, Guma J, et al. Clinical patern and therapeutc results achieved in 1490 patents with germ-cell tumours of the tests: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol. 2002;42(6):553-63.
20. La Vecchia C, Boset C, Lucchini F, Bertuccio P, Negri E, Boyle P, et al. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Annals of Oncology. 2010;21(6):1323-60.
21. Dieckmann KP, Boeckmann W, Brosig W, Jonas D, Bauer HW. Bilateral testcular germ cell tumors. Report of nine cases and review of the literature. Cancer. 1986;57(6):1254- 8.
22. Bulent A, Taner DR, Tolga T, Sertac Y, Celik T, Ferruh Z, et al. Bilateral testcular germ cell tumors in Turkey: increase in incidence in last decade and evaluaton of risk factors in 30 patents. The Journal of urology. 2007;178(1):129-33.
23. Coli A, Bigot G, DellIsola C, Castri F, Rulli F, Massi G. Synchronous bilateral testcular germ cell tumor with diferent histology. Case report and review of the literature. Urologia internatonalis. 2003;71(4):412-7.
24. Bahrami A, Ro JY, Ayala AG. An overview of testcular germ cell tumors. Arch Pathol Lab Med. 2007;131(8):1267- 80.
25. Deotra A, Mathur DR, Vyas MC. A 18 years study of testcular tumours in Jodhpur, western Rajasthan. Journal of Postgraduate Medicine. 1994;40(2):68-70.
26. Javadpour N. The role of biologic tumor markers in testcular cancer. Cancer. 1980;45(7 Suppl):1755-61.
27. Mencel PJ, Motzer RJ, Mazumdar M, Vlamis V, Bajorin DF, Bosl GJ. Advanced seminoma: treatment results, survival, and prognostc factors in 142 patents. Journal of clinical oncology: 1994 Jan;12(1):120-6.
28. Mostof FK, Sesterhenn IATumours of the Tests and Paratestcular Tissue. In Epstein J, Eble J, Sauter G, Sesterhenn IA, eds. World Health Organizaton Classifcaton of tumors: pathology and genetcs of tumours of the urinary system and male genital organs, World Health Organizaton Classifcaton of tumors. Lyon. IARCpress. 2004. p. 217-58.
29. Mead GM, Fossa SD, Oliver RT, Jofe JK, Huddart RA, Roberts JT, et al. Randomized trials in 2466 patents with stage I seminoma: paterns of relapse and follow-up. Journal of the Natonal Cancer Insttute. 2011;103(3):241-9.
30. Oliver RT, Mason MD, Mead GM, von der Maase H, Rustn GJ, Jofe JK, et al. Radiotherapy versus single-dose carboplatn in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005;366(9482):293-300.
31. Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testcular Seminoma: a report on Medical Research Council Trial TE18, European Organisaton for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). Journal of clinical oncology. 2005;23(6):1200-8.
32. Det B, Livi L, Scocciant S, Gacci M, Lapini A, Cai T, et al. Management of Stage II testcular seminoma over a period of 40 years. Urologic oncology. 2009;27(5):534-8.
33. Sturgeon JF, Moore MJ, Kakiashvili DM, Duran I, Anson-Cartwright LC, Berthold DR, et al. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospitals experience. Eur Urol. 2011;59(4):556-62.
34. Stephenson AJ, Bosl GJ, Motzer RJ, Bajorin DF, Stasi JP, Sheinfeld J. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissecton for clinical stage IIA and IIB nonseminomatous germ cell testcular cancer. Journal of clinical oncology. 2007;25(35):5597-602.